AEON Biopharma
AEON
59 hedge funds and large institutions have $172M invested in AEON Biopharma in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 2 closing their positions.
600% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 2
36% more capital invested
Capital invested by funds: $126M → $172M (+$45.8M)
26% more funds holding
Funds holding: 47 → 59 (+12)
0.2% more ownership
Funds ownership: 0.59% → 0.79% (+0.2%)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECP
Empyrean Capital Partners
Los Angeles,
California
|
+$13.6M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
+$8.73M |
| 3 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$7.86M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.86M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$3.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$2.91M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.89M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$91.5K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$28.6K |
| 5 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
-$23K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCM
51
Cinctive Capital Management
New York
| $244K | – | – | – |
|
|
KIM
52
Karpus Investment Management
Pittsford,
New York
| $244K | – | – | – |
|
|
WRBC
53
W.R. Berkley Corp
Greenwich,
Connecticut
| $244K | +$243K | +348 | New |
|
|
AA
54
Ancora Advisors
Cleveland,
Ohio
| $164K | – | – | – |
|
55
Qube Research & Technologies (QRT)
London,
United Kingdom
| $107K | – | – | – |
|
|
RCM
56
Robinson Capital Management
Grosse Pointe Farms,
Michigan
| $101K | +$101K | +145 | New |
|
|
TI
57
Tidal Investments
Milwaukee,
Wisconsin
| $101K | +$101K | +145 | New |
|
|
6CM
58
683 Capital Management
New York
| $97K | +$97.1K | +139 | New |
|
|
GCL
59
Glazer Capital LLC
New York
| $25K | -$1.4K | -2 | -5% |
|
|
60
Verition Fund Management
Greenwich,
Connecticut
| – | -$2.89M | -4,165 | Closed |
|
|
PAM
61
Panagora Asset Management
Boston,
Massachusetts
| – | -$8K | -11 | Closed |
|
AEON Hedge Fund Activity: Q3 2021 in Review
59 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q3 2021, worth a combined $172M — up 36% from $126M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AEON positions and 2 closed out — a net gain of 12 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Empyrean Capital Partners, opening a new position worth an estimated $13.6M. The largest seller was Polar Asset Management Partners, cutting an estimated $2.91M.
- 59 institutional investors held AEON Biopharma (AEON) as of Q3 2021, up from 47 in Q2 2021.
- Funds reported $172M of AEON Biopharma stock for Q3 2021, up 36% quarter-over-quarter.
- 14 funds opened new AEON Biopharma positions in Q3 2021 and 2 closed out, a net change of +12 holders.
- The largest AEON Biopharma buyer in Q3 2021 was Empyrean Capital Partners, an estimated $13.6M added.
- The largest AEON Biopharma seller in Q3 2021 was Polar Asset Management Partners, an estimated $2.91M sold.
Based on aggregated 13F filings for Q3 2021.